Literature DB >> 10715761

ACE inhibitors and heart failure in hospital: any difference between cardiologists and general physicians?

A P Davie1, J J McMurray.   

Abstract

Cardiologists and generalists have been reported to diverge in terms of their self-reported use of angiotensin-converting enzyme (ACE) inhibitors, but information on their actual use of ACE inhibitors has been lacking. In order to assess ACE inhibitor use in patients with heart failure in a teaching hospital and any differences between specialties we studied all patients in the Western Infirmary of Glasgow between 1 April and 1 October 1996 with an echocardiogram showing moderate or severe left ventricular systolic dysfunction (n = 236). We found that most patients were on an ACE inhibitor (66%), 12% had been tried but found to be intolerant, 10% had not been tried because of a contraindication, but 12% had not been tried despite no contraindication. Of those on treatment, 58% were on a dose used in a major survival study (38% of all patients). Most patients were treated by a cardiologist (64%). Of these, more were on an ACE inhibitor (77% vs 53%, p < 0.01), fewer had been tried but found intolerant (11% vs 18%), and fewer had never been tried (11% vs 29%, p < 0.01), irrespective of whether they had a contraindication (5% vs 18%, p < 0.01) or not (6% vs 12%). More were on a dose used in a major survival study (48% vs 31%, p < 0.05). We conclude that, despite improvements over time, ACE inhibitors are still under-used, sometimes without good reason. There are also differences in the use of ACE inhibitors between cardiologists and generalists which may affect outcome, and could affect resource utilisation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10715761      PMCID: PMC1741195          DOI: 10.1136/pgmj.75.882.219

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  5 in total

1.  Simplified echocardiography in the diagnosis of heart failure.

Authors:  R B Willenheimer; B A Israelsson; C M Cline; L R Erhardt
Journal:  Scand Cardiovasc J       Date:  1997       Impact factor: 1.589

2.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Authors:  Salim Yusuf; Bertram Pitt; Clarence E Davis; William B Hood; Jay N Cohn
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

3.  Comparison of different echocardiographic methods with radionuclide imaging for measuring left ventricular ejection fraction during acute myocardial infarction treated by thrombolytic therapy.

Authors:  K Jensen-Urstad; F Bouvier; J Höjer; H Ruiz; J Hulting; B Samad; C Thorstrand; M Jensen-Urstad
Journal:  Am J Cardiol       Date:  1998-03-01       Impact factor: 2.778

4.  Evidence of inadequate investigation and treatment of patients with heart failure.

Authors:  K W Clarke; D Gray; J R Hampton
Journal:  Br Heart J       Date:  1994-06

5.  Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods.

Authors:  A M Choy; D Darbar; C C Lang; T H Pringle; G P McNeill; N S Kennedy; A D Struthers
Journal:  Br Heart J       Date:  1994-07
  5 in total
  4 in total

Review 1.  Contemporary management of heart failure in clinical practice.

Authors:  J G F Cleland
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

2.  A survey of the dose of ACE inhibitors prescribed by general physicians for patients with heart failure.

Authors:  R McMullan; B Silke
Journal:  Postgrad Med J       Date:  2001-12       Impact factor: 2.401

3.  Spironolactone prescribing in heart failure: comparison between general medical patients and those attending a specialist left ventricular dysfunction clinic.

Authors:  R McMullan; B Silke
Journal:  Ulster Med J       Date:  2001-11

4.  Medical therapy doses at hospital discharge in patients with existing and de novo heart failure.

Authors:  Michael J Diamant; Sean A Virani; Winston J MacKenzie; Andrew Ignaszewski; Mustafa Toma; Nathaniel M Hawkins
Journal:  ESC Heart Fail       Date:  2019-06-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.